Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study

European Journal of Health Economics

Volumn 10, Issue 3, 2009, Pages 255-265

  Taylor, Douglas C A ^a   Pandya, Ankur ^a   Thompson, David ^a   Chu, Paula ^a   Graff, Jennifer ^b   Shepherd, James ^c   Wenger, Nanette ^d   Greten, Heiner ^e   Carmena, Rafael ^f   Drummond, Michael ^a,g   Weinstein, Milton C ^a,h  

^a i3 Global   (Canada)

^b PFIZER INC   (United States)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Hanseatisches Herzzentrum Hamburg   (Germany)

^f UNIVERSITY OF VALENCIA   (Spain)

^g UNIVERSITY OF YORK   (United Kingdom)

^h HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cardiovascular disease; Cholesterol lowering; Cost effectiveness; Decision analysis; Markov model; Secondary prevention; Statin therapy

Indexed keywords

ATORVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE COMPARISON; FEMALE; GERMANY; HEALTH CARE COST; HUMAN; MALE; MORTALITY; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SECONDARY PREVENTION; SPAIN; SURVIVAL RATE; SURVIVAL TIME; UNITED KINGDOM;

ANTICHOLESTEREMIC AGENTS; CARDIOVASCULAR DISEASES; COST-BENEFIT ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; EUROPE; HEPTANOIC ACIDS; HUMANS; MARKOV CHAINS; PYRROLES; QUALITY-ADJUSTED LIFE YEARS;

EID: 67649195258     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-008-0126-1     Document Type: Article

References (40)

1. Peterson, S., Peto, V., Rayner, M., Leal, J., Luengo-Fernandez, R., Gray, A.: European cardiovascular statistics. 2005 edition. European health network (2005). http://www.ehnheart.org/files/statistics%202005-092711A.pdf. Cited 28 June 2006
2. Scandinavian Simvastatin Survival Study Group 1994 Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study group Lancet 344 1383 1389
3. FM Sachs MA Pfeffer LA Maye 1996 Cholesterol and recurrent events trial investigators: the effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels N. Engl. J. Med. 335 1001 1009
4. J Shepherd SM Cobbe I Ford 1995 Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N. Engl. J. Med. 333 1301 1307
5. Heart Protection Study Collaborative Group 2002 MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 7 22
6. CP Cannon E Braunwald CH McCabe 2004 Intensive vs. moderate lipid lowering with statins after acute coronary syndromes N. Engl. J. Med. 350 1495 1504 (Pubitemid 38477774)
7. JC LaRosa SM Grundy DD Waters C Shear P Barter JC Fruchart 2005 Intensive lipid lowering with atorvastatin in patients with stable coronary disease N. Engl. J. Med. 352 1425 1435 (Pubitemid 40471450)
8. DD Waters JR Guyton DM Herrington MP McGowan N Wenger C Shear 2004 TNT steering committee and investigators: treating to new targets (TNT) study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am. J. Cardiol. 93 154 158 (Pubitemid 38058722)
9. M Gail R Simon 1985 Testing for qualitative interactions between treatment effects and patient subsets Biometrics 41 361 372
10. JR Cook M Drummond H Glick JF Heyse 2003 Assessing the appropriateness of combining economic data from multinational clinical trials Stat. Med. 22 1955 1976 (Pubitemid 36758398)
11. Pederson, T.R., Wilhelmsen, L., Færgeman, O., Timo, E., Strandberg, M.D., Thorgeirsson, G., Troedsson, L., Kristianson, J., Berg, K., Cook, T.J., Haghfelt, T., Kjekshus, J., Miettinen, T., Olsson, A.G., Pyörälä, K., Wedel, H.: Follow-up study of patients randomized in the Scandinavian Simvastatin Survival Study (4S) of cholesterol lowering. Am. J. Cardiol. 86, 257-262 (2000) (on behalf of the Scandinavian Simvastatin Survival Study group). doi: 10.1016/S0002-9149(00)00910-3
12. I Ford H Murray CJ Packard 2007 Long-term follow-up of the West of Scotland coronary prevention study N. Engl. J. Med. 357 1477 1486 (Pubitemid 47572633)
13. A Rosengren CL Spetz M Köster N Hammar L Alfredsson M Rosén 2001 Sex differences in survival after myocardial infarction Eur. Heart. J. 22 314 322
14. MS Dennis JPS Burn PAG Sandercock JM Bamford DT Wade CP Warlow 1993 Long-term survival after first-ever stroke: the Oxford shire community stroke project Stroke 24 796 800 (Pubitemid 23163551)
15. HM Blackledge J Tomlinson IB Squire 2003 Prognosis for patients newly admitted to hospital with heart failure: survival trends in 12,220 index admissions in Leicestershire 1993-2001 Heart 89 615 620 (Pubitemid 36606202)
16. JP Pell D Walsh J Norrie G Berg AD Colquhoun K Davidson 2001 Outcomes following coronary artery bypass grafting and percutaneous transluminal coronary angioplasty in the stent era: a prospective study of all 9,890 consecutive patients operated on in Scotland over a 2 year period Heart 85 662 666 (Pubitemid 32973463)
17. CL Gwinnutt M Columb R Harris 2000 Outcome after cardiac arrest in adults in UK hospitals: effect of 1997 guidelines Resuscitation 47 2 125 135 (Pubitemid 30734876)
18. Government actuary department interim life tables UK 2002-2004. http://www.gad.gov.uk/Life-Tables/Historical-Interim-life-tables.htm. Cited 05 Jan 2006
19. National Statistics Institute 2003 population projections. http://www.ine.es/inebase/. Cited 10 Feb 2006
20. FC Lampe SG Whincup AG Wannamethee AG Shaper M Walker S Ebrahim 2000 The natural history of prevalent ischaemic heart disease in middle-aged men Eur. Heart. J. 21 1052 1062 (Pubitemid 30352989)
21. A Mosterd B Cost AW Hoes MC de Bruijne JW Deckers A Hofman 2001 The prognosis of heart failure in the general population the Rotterdam study Eur. Heart. J. 22 1318 1327 (Pubitemid 32737624)
22. Statistisches Bundesamt Perioden-Sterbetafeln fur Deutschland 2001/2003. http://www.destatis.de/download/d/bevoe/sterbet03xls. Cited 24 Feb 2006
23. Office of National Statistics: mortality statistics, ONS 2004 population and death rates. http://www.statistics.gov.uk/StatBase/Product.asp?vlnk= 618&Pos=1&ColRank=1&Rank=272. Cited 05 Jan 2006
24. National tables death statistics according to cause of death 2003. http://www.ine.es/inebase/. Cited 10 Feb 2006
25. Federal health monitoring system deaths 2003. http://epp.eurostat.cec.eu. int. Cited 24 Feb 2006
26. PW Sullivan WF Lawrence V Ghushchyan 2005 A national catalog of preference-based scores for chronic conditions in the United States Med. Care. 43 736 749 (Pubitemid 40993769)
27. Department of Health: national tariff costs 2005-2006. National Health Service, 2006. http://www.dh.gov.uk/assetRoot/04/09/15/31/04091531.pdf. Cited 05 Jan 2006
28. National health service drug tariff for England and Wales: Part VIII-Basic prices of drugs. http://www.ppa.org.uk/edt/April-2006v3/mindex.htm. Cited 05 Jan 2006
29. Gisbert, R., Brosa, M.: Base de datos de costes sanitarios. Versión 2.2. Soikos, Barcelona (2005)
30. Catálogo de especialidades farmacéuticas. Consejo General de Colegios Oficiales de Farmacéuticos, Madrid (2005)
31. German diagnosis related groups: the official website the autonomy for German refined-diagnosis related groups. Final report for the advancement of the G-DRG-system for the year 2006. Report browser. http://www.g-drg.de/. Cited 19 May 2006
32. Red List: 2005. Medication information for Germany. http://www.rote- liste.de/. Cited 10 Jun 2006
33. Department of health: reference costs 2004. National health service. http://www.dh.gov.uk/assetRoot/04/10/55/53/04105553.xls. Cited 05 Jan 2006 (2004)
34. Health and social care information centre (England): hospital episode statistics-2004/2005. http://www.hesonline.nhs.uk/Ease/servlet/ContentServer? siteID=1937&categoryID=204. Cited 05 Jan 2006
35. Department for Education (2002) Employment, Labour and Social Affairs (DEELSA). Employment, Labour, and Social Affairs Committee. Summary of results from ischaemic heart disease study. http://www.olis.oecd.org/OLIS/2002DOC.NSF/ 43bb6130e5e86e5fc12569fa005d004c/71e60b595e9eca00c1256bdb003f4ae8/FILE/ JT00128391.PDF. Cited 05 May 2006
36. National Institute for Clinical Excellence guide to the methods of technology appraisal. Draft for consultation (2003) http://www.nice.org.uk/page. aspx?o=205739. Cited 04 Jan 2006
37. Efron, B., Tibshirani, R.J.: An introduction to the bootstrap. Chapman & Hall, New York (1993)
38. J Tsevat KM Kuntz EJ Orav MC Weinstein FM Sacks L Goldman 2001 Cost-effectiveness of pravastatin therapy for survivors of myocardial infarction with average cholesterol levels Am. Heart. J. 141 727 734 (Pubitemid 32378480)
39. B Jönsson M Johannesson J Kjekshus AG Olsson TR Pedersen H Wedel 1996 Scandinavian survival study group: cost-effectiveness of cholesterol lowering. Results from the Scandinavian Simvastatin Survival Study (4S) Eur. Heart. J. 17 1001 1007 (Pubitemid 26252516)
40. TR Pedersen O Faergeman JJP Kastelein AG Olsson MJ Tikkanen I Holme 2005 High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction the IDEAL study: a randomized controlled trial JAMA 294 2437 2445 (Pubitemid 41627921)